Very recent observations from clinical trials have identified SGLT-2 inhibitors as the first class of drugs to improve prognosis in patients with HF and mildly reduced or preserved LVEF% (Vaduganathan et al., 2022), but this must be confirmed by further clinical evaluations. Here, SLC5A2 is linked to hydrops fetalis.